Aberdeen Group plc Sells 67,321 Shares of AbbVie Inc. $ABBV

Aberdeen Group plc decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,255,416 shares of the company’s stock after selling 67,321 shares during the quarter. AbbVie makes up approximately 0.8% of Aberdeen Group plc’s portfolio, making the stock its 14th biggest position. Aberdeen Group plc owned 0.13% of AbbVie worth $511,517,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. acquired a new position in AbbVie during the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie during the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie in the second quarter worth approximately $36,000. Delos Wealth Advisors LLC purchased a new position in shares of AbbVie during the 2nd quarter valued at about $39,000. Finally, Access Investment Management LLC purchased a new position in shares of AbbVie in the second quarter worth about $44,000. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of ABBV opened at $231.57 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market capitalization of $409.28 billion, a PE ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35. The company’s 50-day simple moving average is $223.56 and its 200-day simple moving average is $220.85.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the business earned $2.16 EPS. The company’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

Wall Street Analyst Weigh In

ABBV has been the topic of a number of research reports. UBS Group cut their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Evercore dropped their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $251.00.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.